title: [Pathogenetic ground of including reamberin and cycloferon combination into the therapy program for patients with severe cases of acute tonsillitis of a mixed viral/bacterial etiology].
abstract: The increase of severe cases of acute tonsillitis (AT) is presently marked.  Severe cases of AT disturb immune and metabolic homoeostasis initiating the development of disease.  Therapy optimization is required to select the best treatment.  In  patients with severe cases of AT of mixed viral/bacterial etiology before the treatment it is revealed the increase of general activity of lactatedehydrigenase (LDH) and increase of the level of cathode "anaerobic" factions LDH4+5 and the decline of concentration ATP in the blood. There was a compensatory rise of level of ADP and АМP. The substantial decline of serum interferon (CIF) activity and diminishing maintenance of α-interferon (α-IFN) and γ-interferon (γ-IFN) in the blood of the patients, that testified to oppressing of interferonogenesis.   Treatment of severe cases of AT of mixed viral/bacterial etiology of modern detoxic preparation reamberin and immunoactive preparation cycloferon combination positively influences the studied laboratory indexes. The improvement of power metabolism is marked, that was characterized by normalization of level adenine nucleotides (ATP, АDP, АМP) and general activity of LDH and its izoenzimes spectrum. At the same time the increase of CIF level is set, maintenances α-IFN and γ-IFN in the blood, that testified to the improvement of  interferonogenesis.   The results demonstrate the therapeutic potential of reamberin and cycloferon combination for treatment of patients with AT of mixed viral/bacterial etiology.
authors.forename: V M
authors.initials: VM
authors.lastname: Frolov
authors.forename: N A
authors.initials: NA
authors.lastname: Peresadin
authors.forename: V A
authors.initials: VA
authors.lastname: Tereshin
authors.forename: R B
authors.initials: RB
authors.lastname: Chkhetiani
authors.forename: O V
authors.initials: OV
authors.lastname: Kruglova
mesh_terms: D000166:Acridines / Q000008:administration & dosage*; D000227:Adenine Nucleotides / Q000097:blood; D000293:Adolescent; D000328:Adult; D004359:Drug Therapy, Combination; D005260:Female; D006801:Humans; D007262:Infusions, Intravenous; D007273:Injections, Intramuscular; D007372:Interferons / Q000097:blood; D007527:Isoenzymes / Q000097:blood; D007770:L-Lactate Dehydrogenase / Q000097:blood; D008297:Male; D008536:Meglumine / Q000008:administration & dosage / Q000031:analogs & derivatives*; D008875:Middle Aged; D013386:Succinates / Q000008:administration & dosage*; D014069:Tonsillitis / Q000188:drug therapy / Q000382:microbiology / Q000473:pathology / Q000821:virology
chemical_list: D000166:Acridines; D000227:Adenine Nucleotides; D007527:Isoenzymes; C549374:Reamberin; D013386:Succinates; D008536:Meglumine; D007372:Interferons; D007770:L-Lactate Dehydrogenase; C026430:10-carboxymethyl-9-acridanone